Detalhe da pesquisa
1.
Author Correction: CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
Nature
; 569(7756): E4, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31043737
2.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 382(1): 41-50, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31751012
3.
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(10): 944-957, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877583
4.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Future Oncol
; 19(1): 61-75, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36656302
5.
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
Nature
; 546(7656): 168-172, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28538732
6.
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(2): 113-125, 2018 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29151359
7.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280658
8.
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
Invest New Drugs
; 38(2): 457-467, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31065954
9.
Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
Curr Opin Oncol
; 31(1): 13-17, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30325753
10.
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Future Oncol
; 15(26): 3003-3014, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31339357
11.
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Lancet Oncol
; 19(11): 1468-1479, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262187
12.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Lancet Oncol
; 19(4): 521-536, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545095
13.
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
Br J Clin Pharmacol
; 84(12): 2877-2888, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30171779
14.
A Randomized Clinical Trial of Flex 19G Needles versus 22G Needles for Endobronchial Ultrasonography in Suspected Lung Cancer.
Respiration
; 96(3): 275-282, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29961053
15.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Lancet
; 387(10030): 1837-46, 2016 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26970723
16.
Ceritinib in ALK-rearranged non-small-cell lung cancer.
N Engl J Med
; 370(13): 1189-97, 2014 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24670165
17.
A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer.
Acta Oncol
; 61(6): 773-776, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35574825
18.
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
JAMA
; 317(18): 1844-1853, 2017 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28492898
19.
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Lancet Oncol
; 17(4): 452-463, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26973324
20.
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(6): 822-835, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27132212